Interruption of the sequential release of small and large molecules from tumor cells by low temperature during cytolysis mediated by immune T-cells or complement.
Specific lysis of tumor cells by thymus-derived lymphocytes from alloimmunized mice (T-effector specific lysis) was studied with target cells labeled with isotopes attached to both small ((14)C-labeled nicotinamide) and large ((51)Cr-labeled) molecules. The results confirm and extend previous reports that target cells release small molecules considerably earlier than large molecules during T-effector specific lysis. After interruption of T-effector specific lysis by specific antibody and complement directed against the killer cells, or by ethylenediaminetetraacetic acid, release of both isotopes continued, eventually reaching identical levels of specific release, the value of which represents the fraction of the target cell population which had been committed to die at the time these treatments were applied. On the other hand, release of both isotopes during T-effector specific lysis stops immediately when the cultures are cooled to 0 degrees . Thus, while ethylenediaminetetraacetic acid or specific complement-mediated lysis of the killer cells merely prevents the initiation of any new damage to target cells, cooling to 0 degrees also stops the lytic process in already-damaged target cells. The colloid osmotic phase of target cell lysis induced by specific antibody and complement was similarly stopped at 0 degrees in tumor cells, but not in erythrocytes. Thus, in tumor target cells, both T-effector specific lysis and complement cause a sequential release of progressively larger molecules which can be immediately stopped at any point by cooling to 0 degrees .
D000818:Animals; D000937:Antigen-Antibody Reactions / Q000187:drug effects*; D000961:Antilymphocyte Serum / Q000494:pharmacology; D001345:Autoradiography; D002250:Carbon Radioisotopes; D002460:Cell Line; D002478:Cells, Cultured; D002860:Chromium Radioisotopes; D003080:Cold Temperature; D003165:Complement System Proteins; D003601:Cytotoxicity Tests, Immunologic; D004492:Edetic Acid / Q000494:pharmacology; D007700:Kinetics; D008297:Male; D012515:Mast-Cell Sarcoma / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008970:Molecular Weight; D009243:NAD; D009536:Niacinamide; D009996:Osmotic Fragility; D012513:Sarcoma, Experimental / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
D000961:Antilymphocyte Serum; D002250:Carbon Radioisotopes; D002860:Chromium Radioisotopes; D009243:NAD; D009536:Niacinamide; D003165:Complement System Proteins; D004492:Edetic Acid